Kyowa Hakko launches Immuse immune activator ingredient
Kyowa Hakko Bio Co. Ltd. and parent company Kirin Holdings Co. Ltd. launched Immuse, a unique patented strain of Lactococcus lactis characterized as a heat-killed lactic acid bacteria (paraprobiotic) that supports the immune system.
Photo © iStockphoto.com/Eraxion
Kyowa Hakko Bio Co. Ltd. (New York City, NY) and parent company Kirin Holdings Co. Ltd. launched Immuse, a unique patented strain of Lactococcus lactis characterized as a heat-killed lactic acid bacteria (paraprobiotic) that supports the immune system. It activates plasmacytoid dendritic cells (pDC), which has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, providing broad range immune support.
“A strong immune system is critical for good health, and Immuse is a unique dietary supplement ingredient that offers broad range immune support,” said Elyse Lovett, MS, MBA, senior marketing manager at Kyowa Hakko U.S.A. Inc., in a press release. “With more consumers looking for ways to enhance their immune system and stay healthy throughout the year, we are confident that Immuse, backed by both Kirin Holdings and Kyowa Hakko, will open new doors for consumers desiring a novel option for brand range immune support.”
Immuse is supported by 10 human trials—eight efficacy, two safety studies. A series of safety data including in vitro, in vivo, and in human have been collected. It is stable in a wide variety of applications including tablets, capsules, and gummy formulations.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
